Rakovina Therapeutics Presents Preclinical Data on novel kt-3000 Series Drug Candidates at JCA-AACR Precision Medicine International Conference
16 sept. 2021 09h00 HE
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) ("the Company"), a biopharmaceutical company committed to advancing new cancer therapies based...
Rakovina Therapeutics to Present at the JCA-AACR Precision Medicine International Conference
09 sept. 2021 12h49 HE
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) ("the Company"), a biopharmaceutical company committed to advancing new cancer therapies based...
Rakovina Therapeutics Inc. Announces Second Quarter 2021 Financial Results and Provides Corporate Update
26 août 2021 09h00 HE
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Aug. 26, 2021 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company committed to advancing new cancer therapies based on novel...